Document is current
Any future updates will be listed below
-
Authors
Thapi, Sahityasri
Leiter, Amanda
Galsky, Matthew
Gallagher, Emily J. https://orcid.org/0000-0002-7920-8474
-
Funding
Funding for this research was provided by:
National Cancer Institute (K08CA190770)
- License Information
-
More Information
Article History
Received: 21 June 2019
Accepted: 4 September 2019
First Online: 12 September 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: ST, AL have no disclosures. MG has performed consulting for BioMotiv, Dendreon, Janssen, Merck, GlaxoSmithKline, Lilly, Astellas Pharma, Genentech, Bristol-Myers Squibb, Novartis, Pfizer, EMD Serono, AstraZeneca, Seattle Genetics, Incyte, Aileron Therapeutics, Dracen, Inovio Pharmaceuticals, NuMab, Dragonfly Therapeutics; has stock / ownership interests in Rappta Therapeutics; received research funding from Janssen Oncology, Dendreon, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca, Genentech / Roche. EJG served on advisory board for Novartis.
